Abstract 031: Onyx versus nBCA in MMA Embolization for cSDH: A Single Center Experience of 234 hemispheres

Introduction There is growing evidence supporting endovascular treatment with middle meningeal artery embolization (MMAE) for the treatment of chronic subdural hematoma (cSDH). We aimed to compare Onyx vs. N‐Butyl cyanoacrylate (n‐BCA) as liquid embolic materials for MMAE. Methods We included all el...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed F Doheim, Okkes Kuybu, Mohamed M Salem, Aldo Mendez Ruiz, Ali Fadhil, Abdullah Sultany, Sandra Narayanan, Michael Lang, Alhamza Al‐Bayati, Raul G Nogueira, Bradley Gross
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Stroke: Vascular and Interventional Neurology
Online Access:https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.031
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850268193898102784
author Mohamed F Doheim
Okkes Kuybu
Mohamed M Salem
Aldo Mendez Ruiz
Ali Fadhil
Abdullah Sultany
Sandra Narayanan
Michael Lang
Alhamza Al‐Bayati
Raul G Nogueira
Bradley Gross
author_facet Mohamed F Doheim
Okkes Kuybu
Mohamed M Salem
Aldo Mendez Ruiz
Ali Fadhil
Abdullah Sultany
Sandra Narayanan
Michael Lang
Alhamza Al‐Bayati
Raul G Nogueira
Bradley Gross
author_sort Mohamed F Doheim
collection DOAJ
description Introduction There is growing evidence supporting endovascular treatment with middle meningeal artery embolization (MMAE) for the treatment of chronic subdural hematoma (cSDH). We aimed to compare Onyx vs. N‐Butyl cyanoacrylate (n‐BCA) as liquid embolic materials for MMAE. Methods We included all eligible patients undergoing MMAE for cSDH at University of Pittsburgh Medical Center from April 2019 to December 2022. The main outcomes included radiographic resolution of cSDH with at least 50% reduction of hematoma thickness as a surrogate for treatment success in addition to the need for rescue surgical intervention. Additional outcomes including complication rates and hematoma thickness at the last available follow up. Results A total of 195 patients underwent embolization of 234 hemispheres including 39 bilateral procedures and had available data for final analysis (168 (71.8%) in Onyx group vs. 66 (28.2%) in n‐BCA group). There were no significant differences in age, sex, co‐morbidities, prior SDH/evacuation, pre‐operative cSDH thickness, or use of antithrombotic therapy(P>0.05) while concurrent surgical intervention and midline shift showed a statistically significant difference (P<0.05). On last follow‐up imaging, radiographical treatment success defined as ≥ 50% reduction in hematoma thickness was comparable in Onyx and the n‐BCA groups (50.9% vs 54.8%, P=0.6). Similarly, there was no statistically significant difference in the proportion of patients requiring rescue surgery between both groups (4.8% vs. 7.6%, P=0.4). Excluding concurrent surgical intervention patients yielded similar comparable results. Hematoma thickness at late follow‐up was not statistically significant between both group (8.25 (4.8‐12) mm vs 6.9 (3.1‐11) mm, P =0.11). There was no statistically significant difference in procedural complications between both groups (1.2% vs 1.5%, P=0.84). Conclusion Onyx and n‐BCA in MMAE seem to have comparable outcomes when used in the endovascular treatment of cSDH treatment. Further prospective studies with larger sample sizes are needed to confirm these findings.
format Article
id doaj-art-e15870ec11df4d8bb133c1871a8b90fa
institution OA Journals
issn 2694-5746
language English
publishDate 2023-11-01
publisher Wiley
record_format Article
series Stroke: Vascular and Interventional Neurology
spelling doaj-art-e15870ec11df4d8bb133c1871a8b90fa2025-08-20T01:53:31ZengWileyStroke: Vascular and Interventional Neurology2694-57462023-11-013S210.1161/SVIN.03.suppl_2.031Abstract 031: Onyx versus nBCA in MMA Embolization for cSDH: A Single Center Experience of 234 hemispheresMohamed F Doheim0Okkes Kuybu1Mohamed M Salem2Aldo Mendez Ruiz3Ali Fadhil4Abdullah Sultany5Sandra Narayanan6Michael Lang7Alhamza Al‐Bayati8Raul G Nogueira9Bradley Gross10UPMC Stroke Institute University of Pittsburgh School of Medicine Pennsylvania United StatesUPMC Stroke Institute Pennsylvania United StatesUniversity of Pennsylvania Pennsylvania United StatesUPMC Stroke Institute Pennsylvania United StatesUPMC Stroke Institute Pennsylvania United StateUPMC Stroke Institute Pennsylvania United StatesUPMC Stroke Institute Pennsylvania United StatesDepartment of Neurosurgery University of Pittsburgh School of Medicine Pennsylvania United StatesUPMC Stroke Institute Pennsylvania United StateUPMC Stroke Institute Pennsylvania United StatesDepartment of Neurosurgery University of Pittsburgh School of Medicine Pennsylvania United StatesIntroduction There is growing evidence supporting endovascular treatment with middle meningeal artery embolization (MMAE) for the treatment of chronic subdural hematoma (cSDH). We aimed to compare Onyx vs. N‐Butyl cyanoacrylate (n‐BCA) as liquid embolic materials for MMAE. Methods We included all eligible patients undergoing MMAE for cSDH at University of Pittsburgh Medical Center from April 2019 to December 2022. The main outcomes included radiographic resolution of cSDH with at least 50% reduction of hematoma thickness as a surrogate for treatment success in addition to the need for rescue surgical intervention. Additional outcomes including complication rates and hematoma thickness at the last available follow up. Results A total of 195 patients underwent embolization of 234 hemispheres including 39 bilateral procedures and had available data for final analysis (168 (71.8%) in Onyx group vs. 66 (28.2%) in n‐BCA group). There were no significant differences in age, sex, co‐morbidities, prior SDH/evacuation, pre‐operative cSDH thickness, or use of antithrombotic therapy(P>0.05) while concurrent surgical intervention and midline shift showed a statistically significant difference (P<0.05). On last follow‐up imaging, radiographical treatment success defined as ≥ 50% reduction in hematoma thickness was comparable in Onyx and the n‐BCA groups (50.9% vs 54.8%, P=0.6). Similarly, there was no statistically significant difference in the proportion of patients requiring rescue surgery between both groups (4.8% vs. 7.6%, P=0.4). Excluding concurrent surgical intervention patients yielded similar comparable results. Hematoma thickness at late follow‐up was not statistically significant between both group (8.25 (4.8‐12) mm vs 6.9 (3.1‐11) mm, P =0.11). There was no statistically significant difference in procedural complications between both groups (1.2% vs 1.5%, P=0.84). Conclusion Onyx and n‐BCA in MMAE seem to have comparable outcomes when used in the endovascular treatment of cSDH treatment. Further prospective studies with larger sample sizes are needed to confirm these findings.https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.031
spellingShingle Mohamed F Doheim
Okkes Kuybu
Mohamed M Salem
Aldo Mendez Ruiz
Ali Fadhil
Abdullah Sultany
Sandra Narayanan
Michael Lang
Alhamza Al‐Bayati
Raul G Nogueira
Bradley Gross
Abstract 031: Onyx versus nBCA in MMA Embolization for cSDH: A Single Center Experience of 234 hemispheres
Stroke: Vascular and Interventional Neurology
title Abstract 031: Onyx versus nBCA in MMA Embolization for cSDH: A Single Center Experience of 234 hemispheres
title_full Abstract 031: Onyx versus nBCA in MMA Embolization for cSDH: A Single Center Experience of 234 hemispheres
title_fullStr Abstract 031: Onyx versus nBCA in MMA Embolization for cSDH: A Single Center Experience of 234 hemispheres
title_full_unstemmed Abstract 031: Onyx versus nBCA in MMA Embolization for cSDH: A Single Center Experience of 234 hemispheres
title_short Abstract 031: Onyx versus nBCA in MMA Embolization for cSDH: A Single Center Experience of 234 hemispheres
title_sort abstract 031 onyx versus nbca in mma embolization for csdh a single center experience of 234 hemispheres
url https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.031
work_keys_str_mv AT mohamedfdoheim abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT okkeskuybu abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT mohamedmsalem abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT aldomendezruiz abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT alifadhil abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT abdullahsultany abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT sandranarayanan abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT michaellang abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT alhamzaalbayati abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT raulgnogueira abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres
AT bradleygross abstract031onyxversusnbcainmmaembolizationforcsdhasinglecenterexperienceof234hemispheres